ERAS stock forecast, quote, news & analysis
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more
Why Erasca (ERAS) Stock Is Down -10% in the Last 30 Days
Key Takeaways
- Erasca shares declined roughly 10% over the trailing 30 days, sliding from a mid-September close near $15.36 to approximately $13.79.
- The pullback coincided with the announcement that Chief Operating Officer Nicholas Chetwyn will depart in November 2026, a leadership change that raised execution-risk concerns.
- Over the trailing quarter, the stock has fallen about 27%, giving back a portion of an earlier 2026 rally tied to its pan-RAS oncology program.
- Erasca remains a pre-revenue, clinical-stage biotechnology company with no approved products, leaving the share price highly sensitive to clinical, funding, and leadership news.
- Investors are watching upcoming ERAS-0015 data, the company's cash runway, and an ongoing patent and trade-secret dispute with Revolution Medicines (RVMD).
Erasca (ERAS) Company Overview and Market Position
Erasca, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, focused on discovering and developing therapies for cancers driven by the RAS/MAPK pathway, one of the most frequently mutated signaling networks in human cancer. The company's pipeline centers on oral, targeted inhibitors designed to address difficult-to-treat solid tumors, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer.
Its lead asset, ERAS-0015, is a pan-RAS molecular glue degrader that has generated encouraging early efficacy signals across KRAS-mutant tumors. The broader pipeline includes ERAS-007 (an oral ERK1/2 inhibitor), ERAS-601 (an oral SHP2 inhibitor), ERAS-801 (a CNS-penetrant EGFR inhibitor), and the pan-KRAS candidate ERAS-4001. Because none of these programs has reached approval, Erasca generates no product revenue and relies on equity financing to fund its research and development.
Investors follow Erasca for its concentrated bet on RAS-pathway biology, a high-value but clinically unproven area. The company reported roughly $409 million in cash and marketable securities at the end of the first quarter of 2026 after completing an upsized public offering in January, and management has indicated its capital is expected to fund operations into the first half of 2029.
ERAS Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Erasca shares moved from a closing price near $15.36 to roughly $13.79, a decline of approximately 10%. The move was not a straight line: the stock experienced sharp intraday swings and periods of elevated trading volume, reflecting shifting sentiment among holders of a name that had surged earlier in the year.
The longer-term picture is more pronounced. Over the trailing quarter, from a mid-July close near $19.02 to the current level, the stock has fallen roughly 27%. This means the 30-day decline is part of a broader multi-month downtrend rather than an isolated event. After peaking above $21 in mid-July, Erasca steadily gave back gains, with intermittent rallies that failed to hold, underscoring the stock's volatility and its dependence on discrete clinical and corporate catalysts.
What Drove ERAS Stock Price in the Last 30 Days
The most visible near-term catalyst was a leadership transition. Erasca disclosed that Chief Operating Officer Nicholas Chetwyn would depart in November 2026, with his responsibilities redistributed among other executives. Although the company framed the move as a realignment ahead of future commercialization, markets frequently read abrupt C-suite departures as a signal of internal strain or strategic uncertainty, and the announcement pressured the shares.
Beyond that event, the 30-day decline reflected profit-taking after an unusually strong run. Having advanced sharply on early ERAS-0015 data, the stock entered a period with few scheduled data readouts, leaving it exposed to repositioning by traders and funds. Persistent themes also weighed on sentiment: Erasca has no revenue, continues to burn cash, and may require additional equity financing, which carries dilution risk. An outstanding securities class action and a patent and trade-secret dispute involving the lead asset added to the uncertainty, keeping conviction-driven buyers on the sidelines during the period.
What Drove ERAS Stock Performance Over the Last Quarter
The quarterly decline reflects investors digesting a sharp rally that preceded it. In April 2026, Erasca reported Phase 1 results for ERAS-0015 that showed encouraging efficacy but also raised safety questions, including a patient death, prompting a reassessment of the program's risk-reward. The company followed with a significantly wider first-quarter net loss of approximately $183.4 million, driven in part by a $150 million in-process research and development charge to secure expanded global rights to ERAS-0015.
Over the quarter, the stock traded lower as the market weighed that concentrated single-asset bet against a competitive and fast-moving RAS oncology field. A clinical trial collaboration with Merck (MRK) to study ERAS-0015 in combination with KEYTRUDA provided external validation, but it was not enough to offset broader risk-off pressure across pre-commercial biotech, ongoing legal overhangs, and the absence of near-term catalysts. The result was a steady erosion from the mid-July peak through the current level.
Trending AI Robots
For investors seeking a more systematic approach to a volatile name like Erasca, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron operates hundreds of AI trading bots that track thousands of tickers, but only the top-performing and most relevant bots are featured in this section. Each bot differs in strategy, timeframe, and performance metrics, allowing users to compare approaches rather than rely on a single model. The page is designed to help traders and investors identify currently popular and effective automated strategies, with the understanding that past performance does not guarantee future results. Exploring the Trending AI Robots section can provide additional context for those evaluating how quantitative systems are positioning across the market.
ERAS Stock Forecast Drivers: What Investors Should Watch Next
The path forward for Erasca will likely hinge on clinical execution and data flow. Additional ERAS-0015 monotherapy expansion and combination results are expected between late 2026 and the first half of 2027, and initial readouts for ERAS-4001 represent another potential catalyst. How management integrates the departing COO's responsibilities will also be closely watched as the company builds toward potential commercialization.
Financial and legal factors remain central. Investors should monitor the company's cash runway, any future capital raises, and developments in the Revolution Medicines patent and trade-secret dispute and the related securities litigation. Broader macro conditions, including risk appetite for pre-revenue biotech and the cost of capital, will continue to influence the stock's volatility. As with any clinical-stage oncology company, outcomes are binary and depend heavily on trial results and regulatory feedback.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ERAS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ERAS turned positive on October 20, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in 52 of 55 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ERAS as a result. In 83 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +5.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in 209 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
ERAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where ERAS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ERAS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.150) is normal, around the industry mean (3.051). P/E Ratio (-15.411) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology